Open Access. Powered by Scholars. Published by Universities.®
- Institution
-
- Chapman University (35)
- University of Kentucky (8)
- University of Nebraska Medical Center (8)
- Ohio Northern University (6)
- Virginia Commonwealth University (5)
-
- University of Tennessee Health Science Center (4)
- University of Connecticut (3)
- James Madison University (2)
- The British University in Egypt (2)
- University of Louisville (2)
- University of Malaya (2)
- Aga Khan University (1)
- Central Washington University (1)
- Cleveland State University (1)
- Florida Institute of Technology (1)
- Kennesaw State University (1)
- LSU New Orleans (1)
- Liberty University (1)
- Old Dominion University (1)
- Otterbein University (1)
- Roseman University of Health Sciences (1)
- Seton Hall University (1)
- Technological University Dublin (1)
- The University of Southern Mississippi (1)
- Universitas Indonesia (1)
- University of Arkansas, Fayetteville (1)
- University of Central Florida (1)
- University of Mississippi (1)
- University of South Carolina (1)
- Western Kentucky University (1)
- Keyword
-
- Cancer (4)
- Drug delivery (4)
- SiRNA (4)
- CYP3A (3)
- Microfluidics (3)
-
- Pharmacokinetics (3)
- Blood-brain barrier (2)
- Brain (2)
- CRISPR (2)
- Chemotherapeutics (2)
- Cytochrome P450 (2)
- Delivery (2)
- Doxorubicin (2)
- Formulation (2)
- Lipid nanoparticles (2)
- Microsomes (2)
- Midazolam hydroxylation (2)
- Monoclonal Antibodies (2)
- Nanoparticles (2)
- PK/PD (2)
- Pharmacodynamics (2)
- Pneumonia (2)
- RNA therapeutics (2)
- Topotecan (2)
- 28-day toxicology study (1)
- 419 (1)
- ABC transporter (1)
- AIDS (1)
- ART (1)
- Addiction Pharmacotherapy (1)
- Publication Year
- Publication
-
- Pharmacy Faculty Articles and Research (25)
- Theses & Dissertations (8)
- Pharmacy and Wellness Review (6)
- Theses and Dissertations--Pharmacy (6)
- Theses and Dissertations (4)
-
- Theses and Dissertations (ETD) (4)
- Pharmacy Faculty Books and Book Chapters (3)
- Electronic Theses and Dissertations (2)
- Honors Scholar Theses (2)
- Pharmaceutical Sciences (MS) Theses (2)
- Physician Assistant Capstones, 2020-current (2)
- Student Scholar Symposium Abstracts and Posters (2)
- UROP Posters (2)
- All Master's Theses (1)
- Annual Research Symposium (1)
- Department of Biological & Biomedical Sciences (1)
- Doctoral (1)
- Doctoral Projects (1)
- ENGL 1102 Showcase (1)
- Honors Theses (1)
- Honors Undergraduate Theses (1)
- Journal of Law and Health (1)
- LSU New Orleans Theses and Dissertations (1)
- Library Articles and Research (1)
- Masters Theses & Specialist Projects (1)
- Mathematics & Statistics Faculty Publications (1)
- Mathematics, Physics, and Computer Science Faculty Articles and Research (1)
- Nanotechnology Research Centre (1)
- Pharmaceutical Sciences Faculty Publications (1)
- Pharmaceutical Sciences and Research (1)
- Publication Type
Articles 91 - 96 of 96
Full-Text Articles in Pharmaceutical Preparations
Discovery Of Quinic Acid Derivatives As Oral Anti-Inflammatory Agents, Kui Zeng
Discovery Of Quinic Acid Derivatives As Oral Anti-Inflammatory Agents, Kui Zeng
Theses and Dissertations (ETD)
Quinic acid (QA) esters found in hot water extracts of Uncaria tomentosa (a.k.a. Cat’s claw) exert anti-inflammatory activity through mechanisms involving inhibition of the pro-inflammatory transcription factor nuclear factor kappa B (NF-κB). Herein, we described the synthesis and biological testing of novel QA derivatives. Inhibition of NF-κB was assessed using A549 (Type II alveolar epithelial-like) cells that stably express a secreted alkaline phosphatase (SEAP) reporter driven by an NF-κB response element. A549- NF-κB cells were stimulated with TNF-α (10 ng/mL) in the presence or absence of QA derivative for 18 hours followed by measurement of SEAP activity. Amide substitution at …
Incentives For Orphan Drug Research And Development In The United States, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, Sheryl L. Szeinbach, Jay Visaria
Incentives For Orphan Drug Research And Development In The United States, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, Sheryl L. Szeinbach, Jay Visaria
Pharmacy Faculty Articles and Research
Background: The Orphan Drug Act (1983) established several incentives to encourage the development of orphan drugs (ODs) to treat rare diseases and conditions. This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity life of orphan new molecular entities (NMEs) approved in the US between 1983 and 2007.
Methods: Primary data sources were the FDA Orange Book, the FDA Office of Orphan Drugs Development, and the US Patent and Trademark Office. Data included all orphan designations and approvals listed by the FDA and all NMEs approved by the FDA during …
The Role Of Multi-Drug Resistance Associated Protein 4 And P-Glycoprotein In Resistance Of Neuroblastoma To Topotecan And Irinotecan, Patricia Kellie Turner
The Role Of Multi-Drug Resistance Associated Protein 4 And P-Glycoprotein In Resistance Of Neuroblastoma To Topotecan And Irinotecan, Patricia Kellie Turner
Theses and Dissertations (ETD)
High-risk neuroblastoma presents a significant therapeutic challenge because the 5-year survival rate remains less than 30% despite the use of surgery, multi-agent chemotherapy, radiation, and autologous bone marrow transplant. Novel therapeutic modalities are under development. The camptothecin analogs topotecan and irinotecan have been identified as successful cytotoxic agents. For topotecan, pharmacokinetically guided dosing to achieve a systemic exposure associated with preclinical anti-tumor activity in neuroblastoma xenograft models is feasible and has elicited favorable responses in children with high-risk neuroblastoma. However, some children with high-risk disease did not respond to the putatively effective topotecan systemic exposure. These children represent a subset …
Cost Prevention Of Hiv, Jerika Lam
Cost Prevention Of Hiv, Jerika Lam
Pharmacy Faculty Articles and Research
"Since the introduction of highly active antiretroviral therapy (HAART) in the late 1990s, management of patients with human immunodeficiency virus (HIV) infection has improved where they are living longer and with fewer incidences of opportunistic illnesses. Furthermore, significant progress has been made in the understanding of the disease, the ability to quantify viral load and correlate with clinical outcomes, genotypic and phenotypic resistance assays designed to assess viral susceptibility, and a heightened awareness and appreciation of the importance of treatment adherence to ensure virologic suppression.' In spite of the benefits that HIV-infected patients may have acquired in terms of more …
Analysis Of Loratadine By Potentiometry And Reverse-Phase High Performance Liquid Chromatography, Kian Yong Puen
Analysis Of Loratadine By Potentiometry And Reverse-Phase High Performance Liquid Chromatography, Kian Yong Puen
Student Works (2000-2009)
A non-aqueous titration method was developed to assay Loratadine bulk active and a High Performance Liquid Chromatography (HPLC) method was developed to determine Loratadine's manufacturing impurity. The HPLC method was also suitable for simultaneously assay and related substance determination of Loratadine pharmaceutical preparations. In the tritation method, glacial acetic acid was chosen as an amphiprotic solvent. Loratadine ionised in glacial acetic acid; the conjugated base of acetic acid (Ac·), was then titrated with standardised perchloric acid. The method was validated found to be precise, linear and robust. Reverse-phase HPLC method using a Novapak Cl8 column with a CH3CN: I0mM K2HPO4 …
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
Pharmacy Faculty Articles and Research
"The lifetime prevalence of major depressive disorder in women is 10 to 25%, with an average age of onset in the mid-20s.1 Over the nine years that the selective serotonin reuptake inhibitors (SSRis) have been available, for many prescribers, they have become first-line agents in the treatment of depression. In addition, sorne of them are also being used in the treatment of obsessive- compulsive disorder and panic disorder. In light of these facts, itis not unlikely that women of childbearing age would be treated with one of the SSRis. In considering the risks of exposing a fetus to an SSRI, …